Atopic Dermatitis Market, By Drug Class (Corticosteroids, Emollients/Moisturizers, IL-4 & PDE4 Inhibitors, Calcineurin Inhibitors Antibiotics, and Other Drug Classes), By Type of Administration (Topical, Oral, and Injectable), By Prescription Type (Over-the-counter (OTC) and Prescription), and By Geography (North America, Europe, Asia Pacific, Middle East and Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023

Code : CMI712

Pages :170

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

Global Atopic Dermatitis Market: Key Developments

In August 2022, Chugai Pharmaceutical Co., Ltd. announced that Maruho Co., Ltd. announced the launch of anti-IL-31 receptor A humanized monoclonal antibody Mitchga Subcutaneous Injection for the treatment of itching associated with atopic dermatitis. Mitchga is approved by the Ministry of Health, Labour and Welfare (MHLW) on March 28, 2022.

In June 2022, Otsuka Pharmaceutical Co. (Otsuka) announced the launch of Moizerto Ointment (difamilast), a new treatment for atopic dermatitis in Japan.

In February 2022, the U.S. Food and Drug Administration (USFDA) approved the use of Opzelura (ruxolitinib) cream for the topical treatment of mild to moderate atopic dermatitis. They noted that it's for the short-term, non-continuous treatment of chronic atopic dermatitis.

In May 2020, the U.S. FDA approved Dupixent (dupilumab) for children aged six to 11 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Global Atopic Dermatitis Market: Key Companies Insights

The global atopic dermatitis market is highly competitive. This is attributed to the rise in burden or prevalence of atopic dermatitis across the globe, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global atopic dermatitis market are Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.